Identification | Back Directory | [Name]
3-Indolizinebutanoic acid, 1-[4-[(1S)-1-[4-(2-methylpropyl)phenyl]butoxy]benzoyl]- | [CAS]
146939-64-2 | [Synonyms]
FK687 TF505 TF-505 FK-687 TF 505 FR-146687 3-Indolizinebutanoic acid, 1-[4-[(1S)-1-[4-(2-methylpropyl)phenyl]butoxy]benzoyl]- | [Molecular Formula]
C33H37NO4 | [MOL File]
146939-64-2.mol | [Molecular Weight]
511.65 |
Hazard Information | Back Directory | [Uses]
FR-146687 (FK 687) is a selective and orally active 5α-reductase inhibitor with IC50s of 1.7 nM and 4.6 nM for rat and human 5α-reductases, respectively. FR-146687 shows no inhibitory effects on other steroid oxidoreductases[1]. | [in vivo]
FR-146687 (0.032-3.2 mg/kg; po; 2, 7, 14, or 21 days) dose-dependently reduces ventral prostate and seminal vesicle weight at doses above 0.1 mg/kg[1].
Animal Model: | 4-week-old immature castrated male rats injected with Testosterone propionate (TP)[1] | Dosage: | 0.032 mg/kg, 0.32 mg/kg, 3.2 mg/kg | Administration: | po; 2, 7, 14, or 21 days | Result: | Dose-dependently reduced ventral prostate and seminal vesicle weight at doses above 0.1 mg/kg.
|
| [References]
[1] O Nakayama, et al. FR146687, a novel steroid 5 alpha-reductase inhibitor: in vitro and in vivo effects on prostates. Prostate. 1997 Jun 1;31(4):241-9. DOI:10.1002/(sici)1097-0045(19970601)31:4<241::aid-pros5>3.0.co;2-n |
|
|